Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Affimed (0HL9) Share Price & Analysis

0 Followers

0HL9 Stock Chart & Stats

$0.02$0.00(0.00%)
At close: 4:30 PM GMT
$0$0.5$1May 6May 19Jun 2Jun 16Jul 1Jul 14Jul 28
Day’s Range
$0.02 - $0.02
52-Week Range
$0.02 - $0.02
Previous Close
$0.02
Volume
N/A
Average Volume (3M)
0
Market Cap
$1,523
Enterprise Value
$41.58M
Total Cash (Recent Filing)
$24.94M
Total Debt (Recent Filing)
$12.89M
Price to Earnings (P/E)
0.0
Beta
-4.81
Next Earnings
N/A
EPS Estimate
N/A
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Progress

Affimed's clinical proof of concept in multiple assets indicates strong potential for future product success, enhancing its competitive position in the immuno-oncology space.

Operational Efficiency

Improved operational efficiency, as evidenced by reduced cash burn, suggests better management of resources, which is crucial for sustaining long-term operations.

Strategic Partnerships

A focus on strategic partnerships can provide financial support and accelerate the development of therapeutic candidates, strengthening Affimed's market position.

Bears Say

Revenue Decline

Significant revenue decline indicates challenges in monetizing products, which could impact long-term financial sustainability and growth prospects.

Decreased Cash Reserves

Reduced cash reserves limit financial flexibility and could hinder the company's ability to fund ongoing and future clinical trials, impacting growth.

High Leverage

Increased leverage can strain cash flows and limit strategic options, posing a risk to financial health and operational stability over the long term.

Affimed News

0HL9 FAQ

What was Affimed’s price range in the past 12 months?
Affimed lowest share price was $0.02 and its highest was $0.02 in the past 12 months.
What is Affimed’s market cap?
Affimed’s market cap is $1,523.
When is Affimed’s upcoming earnings report date?
Affimed’s next earnings report is estimated for Aug 07, 2025 (not yet confirmed), which is 464 days ago.
How were Affimed’s earnings last quarter?
Affimed released its earnings results on May 21, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.534 by $0.184.
Is Affimed overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Affimed pay dividends?
Affimed pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Affimed dividends here
What is Affimed’s EPS estimate?
Affimed’s EPS estimate is -0.37.
How many shares outstanding does Affimed have?
Affimed has 15,227,463 shares outstanding.
What happened to Affimed’s price movement after its last earnings report?
Affimed reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.534. Following the earnings report the stock price went down -55.056%.
Which hedge fund is a major shareholder of Affimed?
Hedge funds hold Affimed shares: the largest hedge-fund position in Affimed is 138,276,652 shares, and hedge funds decreased their holdings by 4.4M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology